COMMUNIQUÉS West-GlobeNewswire

Savara Reports First Quarter 2018 Financial Results and Provides Business Update
09/05/2018
Molgradex Phase 3 IMPALA study enrollment on track for completion in Q3 2018 AeroVanc Phase 3 AVAIL study enrollment on track for completion in Q1 2019 Molgradex Phase 2a OPTIMA study enrollment on track for completion [...]
FibroGen Reports First Quarter 2018 Financial Results
09/05/2018
Pamrevlumab Data to be Presented at ATS 2018 and ASCO 2018 Roxadustat U.S. Phase 3 Clinical Studies on Track to Readout in Fourth Quarter 2018 Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN [...]
Collegium Reports First Quarter Financial Results and Provides Corporate Update
09/05/2018
Net revenue of $63.7 million, compared to $10.8 million in Q4 2017 Xtampza ER prescriptions grew by 72% in the first quarter Integration of the Nucynta franchise into the commercial organization Conference call [...]
Sientra Reports First Quarter 2018 Financial Results
09/05/2018
Achieves Highest Net Sales in Company’s History Received FDA Approval of PMA Supplement Launched OPUS™ Branded Breast Products and miraDry fresh™ Enhanced Protocol Completed Upsized Follow-on Public Offering of Common [...]
Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity
09/05/2018
Longer-term data from open label study show reductions in hyperphagia and body weight In vitro analyses advance understanding of setmelanotide’s activity at the MC4 receptor, a part of a key pathway regulating energy [...]
Zogenix Provides Corporate Update and Reports First Quarter Financial Results
09/05/2018
Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndrome Study 1504 fully enrolled with 87 randomized [...]
Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
09/05/2018
BOSTON, May 09, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM ), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity [...]
Cara Therapeutics Reports First Quarter 2018 Financial Results
09/05/2018
Conference call today at 4:30 p.m. ET STAMFORD, Conn., May 09, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA ), a biopharmaceutical company focused on developing and commercializing new chemical [...]
MannKind Corporation Reports 2018 First Quarter Financial Results
09/05/2018
Conference Call to Begin Today at 5:00 PM ET Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 (+234% under the 2017 revenue recognition model) Q1 2018 Net Cash Used in Operating Activities was $21.7 [...]
Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update
09/05/2018
Biologics License Application (BLA) Remains on Track to be Submitted by the End of May 2018 Leadership Team Expanded with Appointment of Dr. Robert Iannone, Head of Research & Development and Chief Medical Officer [...]
Adverum Biotechnologies Reports First Quarter 2018 Financial Results and Provides Corporate Update
09/05/2018
MENLO PARK, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM ), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today reported [...]
Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma
09/05/2018
MADISON, Wis., May 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB ), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of [...]
Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
09/05/2018
Highlighting the Dose Response and Mechanism of Action of Larazotide Acetate In large animals, larazotide replicated its mechanism of action by renormalizing the dysfunctional intestinal barrier In spite of damage from [...]
Endonovo Therapeutics Signs Distribution Agreement with Plagens Medical Consultants for its Pain Relief Electroceutical™ SofPulse®
09/05/2018
LOS ANGELES, CA, May 09, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of Electroceutical™ Therapies, today announced a distribution [...]
Photocure ASA: Annual general meeting held
09/05/2018
Oslo, Norway, 9 May 2018: Photocure ASA (OSE: PHO), held its annual general meeting on 9 May 2018 at 17:00 hours (CET). All proposals were resolved as presented in the notice convening the annual general meeting dated [...]
Health Foundation of South Florida Promotes Janisse Schoepp Ph.D. to Vice President of Operations and Strategy
09/05/2018
Dr. Schoepp to guide Health Foundation's new strategic focus Miami, FL, May 09, 2018 (GLOBE NEWSWIRE) -- Health Foundation of South Florida, the largest philanthropy dedicated to improving health in Broward, Miami-Dade [...]
GENFIT : ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF JUNE 15, 2018 - AVAILABILITY OF PREPARATORY DOCUMENTS
09/05/2018
GENFIT: ordinary and extraordinary SHAREHOLDERS' meeting of june 15, 2018 - AVAILABILITY OF PREPARATORY DOCUMENTS Lille (France), Cambridge (Massachusetts, United States), May 9, 2018 - GENFIT (Euronext: GNFT - ISIN: [...]
GENFIT : ASSEMBLEE GENERALE ORDINAIRE ET EXTRAORDINAIRE DU 15 JUIN 2018 - MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES
09/05/2018
GENFIT : ASSEMBLEE GENERALE ORDINAIRE ET EXTRAORDINAIRE DU 15 JUIN 2018 - MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES Lille (France), Cambridge (Massachusetts, Etats-Unis), le 9 mai 2018 - GENFIT ( [...]
Orion Corporation: Managers' transactions - Karvonen Eero kuolinpesä
09/05/2018
ORION CORPORATION MANAGERS' TRANSACTIONS 9 MAY 2018 at 18.30 EEST Orion Corporation: Managers' transactions - Karvonen Eero kuolinpesä Orion Corporation has received the following disclosure under Market Abuse [...]

Pages